|Dr. Pankaj Mohan||Founder, Chairman, Pres & CEO||1.39M||N/A||1965|
|Mr. Lawrence A. Kenyon||CFO, Principal Accounting Officer & Corp. Sec.||327.09k||N/A||1966|
|Dr. Kenneth M. Bahrt||Chief Medical Officer||N/A||N/A||1953|
|Rick Gregory||Director of Marketing & Communications||N/A||N/A||N/A|
|Dr. Stephen J. McAndrew||Sr. VP of Bus. Strategy & Devel.||N/A||N/A||1954|
Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Oncobiologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.